Xenetic Biosciences (NASDAQ:XBIO) Releases Earnings Results

Xenetic Biosciences (NASDAQ:XBIO) posted its quarterly earnings results on Tuesday. The company reported ($0.20) earnings per share for the quarter, FiscalAI reports. Xenetic Biosciences had a negative return on equity of 42.43% and a negative net margin of 70.03%.The company had revenue of $0.81 million during the quarter.

Xenetic Biosciences Price Performance

Xenetic Biosciences stock opened at $3.18 on Thursday. The company has a market capitalization of $7.29 million, a price-to-earnings ratio of -2.65 and a beta of 2.20. Xenetic Biosciences has a one year low of $1.90 and a one year high of $13.93. The company’s fifty day moving average price is $2.99 and its two-hundred day moving average price is $2.64.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC bought a new position in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned about 0.60% of Xenetic Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.